Structure (Image 1)
Chemical structure of Buprenorphine, showing its multi-ring molecular framework with hydroxyl, methoxy, and tertiary butyl groups.*
Buprenorphine Patch, Extended Release
Product Images NDC 0093-3239
26 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 0093-3239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fige (Image 10)
Illustration diagram of a Buprenorphine transdermal extended-release patch showing its protective liner with a slit for removal and the backing layer with adhesive. The image details the patch's layered structure for application.*
Figf (Image 11)
An instructional diagram showing the removal of the protective liner from a transdermal patch. The image labels the protective liner being peeled away to expose the backing layer with adhesive. It depicts hands holding the patch to demonstrate proper handling before application.*
Figg (Image 12)
An instructional illustration showing a person applying a square transdermal patch to the upper chest area. The diagram emphasizes the correct placement of the patch for a transdermal drug delivery system.*
Figh (Image 13)
An instructional line drawing showing the application of a transdermal patch to the chest of a person. The image depicts one hand holding the patch against the upper chest, with the other hand pressing it in place. This illustration is relevant to the use of Buprenorphine extended release transdermal patches by Teva Pharmaceuticals USA.*
Figi (Image 14)
An instructional illustration showing a person applying a transdermal patch to the upper chest area near the shoulder. The image demonstrates the proper placement of a Buprenorphine extended-release transdermal patch on the skin for drug administration.*
Figj (Image 15)
An instructional illustration showing hands holding and viewing a disposal unit card with stepwise pictorial instructions for proper disposal of the medication patch, including removal, placement, and sealing steps.*
Figk (Image 16)
An instructional line drawing showing hands peeling off backing from a rectangular transdermal patch, demonstrating the application process for a medication patch.*
Figl (Image 17)
An instructional illustration labeled Figure L showing a hand peeling a protective backing from a transdermal patch on an arm. The image demonstrates how to properly remove the backing before application.*
Figm (Image 18)
An instructional diagram labeled 'Figure M' showing a hand applying a rectangular transdermal patch to the skin. The illustration emphasizes proper placement of the patch for the Buprenorphine extended-release transdermal delivery system.*
Fign (Image 19)
An instructional illustration showing two hands peeling the protective backing off a Buprenorphine transdermal patch. The image demonstrates the process of preparing the patch for application on the skin.*
Fig1 (Image 2)
A cross-sectional illustration diagram showing the layered structure of a Buprenorphine transdermal patch. The labeled layers include 1. Backing Layer with Adhesive, 2. Separating Layer, 3. Drug/Polymer Adhesive Matrix, and 4. Peel-off Release Liner.*
Figo (Image 20)
An instructional illustration showing a hand placing a rectangular object into a container, labeled as Figure O. This image likely demonstrates proper disposal or handling procedures related to the product or its packaging.*
Figp (Image 21)
An instructional line drawing illustrating a hand placing a small square patch inside the rim of a toilet bowl, demonstrating a disposal method. This image is associated with the use of a Buprenorphine transdermal patch product by Teva Pharmaceuticals USA, Inc.*
5 Mcg/hour (Image 22)
Packaging label for Buprenorphine Transdermal System 5 mcg/hour, a human prescription drug delivered via extended-release transdermal patch. The label shows the dosage strength of 5 micrograms per hour and is manufactured by Teva Pharmaceuticals USA, Inc. It includes information about the system delivering buprenorphine for seven days, warnings about serious respiratory risks, and mentions the package contains 4 transdermal systems and 4 disposal units.*
10 Mcg/hour (Image 23)
Packaging label for Buprenorphine Transdermal System 7.5 mcg/hour by Teva Pharmaceuticals USA, Inc. The label highlights the extended-release transdermal patch delivering 7.5 micrograms per hour. It includes usage warnings, quantity details (4 transdermal systems and 4 disposal units), and instructions for dispensers. The label also displays the NDC 0093-3239-40 and Teva logo.*
15 Mcg/hour (Image 24)
Buprenorphine Transdermal System 10 mcg/hour packaging label from Teva Pharmaceuticals USA, Inc. The label indicates it is an extended-release patch for systemic delivery of 10 mcg per hour over seven days. The box contains 4 transdermal systems and 4 disposal units, with dosing warnings and dispensation instructions clearly noted.*
20 Mcg/hour (Image 25)
Packaging label for Buprenorphine Transdermal System 15 mcg/hour by Teva Pharmaceuticals USA, Inc. The label shows this is a human prescription drug patch with extended-release delivery. It includes warnings about serious breathing problems and usage instructions, noting it contains 4 transdermal systems and 4 disposal units. The label also states it is for use in opioid-experienced patients only.*
Image 26
Packaging label for Buprenorphine Transdermal System 20 mcg/hour by Teva Pharmaceuticals USA, Inc. The label indicates a transdermal patch with systemic delivery of 20 mcg per hour for seven days. The carton includes handling warnings, product NDC 0093-3659-40, and contents of 4 transdermal systems and 4 disposal units. The label emphasizes that it is for experienced opioid-tolerant patients only.*
Fig2 (Image 3)
A line graph depicting plasma concentration of Buprenorphine over 26 days following application of a 10 mcg/hour Buprenorphine Transdermal System every 7 days for three cycles. The X-axis indicates time in days, and the Y-axis shows concentration in pg/mL. The graph highlights concentration peaks and declines with error bars and marks the patch removal on day 21.*
Fig3 (Image 4)
A line graph comparing the percentage of patients improved versus the percent of reduction/improvement in pain, for placebo and Buprenorphine Transdermal System 10/20. The y-axis shows percent patients improved (0-100%), and the x-axis shows percent reduction/improvement in pain from >0% to 100%. The Buprenorphine Transdermal System consistently shows higher patient improvement percentages than placebo across pain reduction levels.*
Fig4 (Image 5)
A line graph comparing the percentage of patients improved versus the percent of reduction/improvement in pain for Buprenorphine Transdermal System 5 and 20. The x-axis shows incremental percentage thresholds of pain reduction from >0% to 100%, while the y-axis represents the percentage of patients improved, ranging from 0% to 100%. Two lines represent data for the 5 ug/h dose (dashed) and the 20 ug/h dose (solid), showing higher patient improvement percentages with the 20 ug/h strength across most pain reduction levels.*
Figa (Image 6)
Illustration showing the application sites for Buprenorphine transdermal patch on a human torso. The patch is depicted on the upper arm and upper chest area from different frontal and side views, indicating appropriate locations for transdermal placement.*
Figb (Image 7)
An illustration showing the upper back of a human torso with two square transdermal patches applied side-by-side on the left upper back near the shoulder. The figure is labeled as Figure B.*
Figc (Image 8)
An instructional line drawing showing a person holding a small pair of scissors near the upper chest area, illustrating the act of cutting the Buprenorphine transdermal patch, consistent with application or removal instructions.*
Figd (Image 9)
An instructional diagram depicting hands cutting open a sealed packet or pouch with scissors, demonstrating how to open the product packaging for Buprenorphine transdermal patches by Teva Pharmaceuticals USA, Inc.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
